The economics of therapeutic advances: the paradigm of sympathetic suppression in chronic heart failure

Arch Intern Med. 1999 Dec;159(22):2634-6. doi: 10.1001/archinte.159.22.2634.

Authors

I Gavras¹, A J Manolis, H Gavras

Affiliation

¹ Department of Medicine, Boston University School of Medicine, MA 02118, USA.

PMID: 10597753
DOI: 10.1001/archinte.159.22.2634

No abstract available

MeSH terms

Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Cardiotonic Agents / therapeutic use
Clonidine / therapeutic use
Diuretics / therapeutic use
Drug Industry
Economics, Pharmaceutical*
Heart Failure / drug therapy*
Humans
Randomized Controlled Trials as Topic
Sympathetic Nervous System / drug effects*
Sympatholytics / therapeutic use

Substances

Angiotensin-Converting Enzyme Inhibitors
Cardiotonic Agents
Diuretics
Sympatholytics
Clonidine